Announced
Completed
Financials
Sources
Tags
Acquisition
biotherapeutics
Completed
Domestic
Private
China
Venture Capital
Private Equity
Pharmaceuticals
Minority
Friendly
Synopsis
CDH, an alternative asset management firm, led a $108m Series C funding round in IASO Biotherapeutics, a developer of cancer biotherapeutics. Other investors include CCB International, Everbright, Co-Stone Capital, CNCB Capital, Plaisance Capital and GL Ventures. “The proceeds raised will enable us to advance our innovative pipeline and consolidate our strategic positioning and advantages in immuno-oncology and autoimmune diseases. With an innovative and pioneering spirit and strong execution ability, our team will continue to commit ourselves to bringing life-changing therapies to patients worldwide," Wen Wang, IASO Bio CEO & CMO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.